If you or a loved one has taken Reglan and developed involuntary movements, you may wonder how certain the link is and what monitoring can achieve. Decades of pharmacovigilance have established tardive dyskinesia as a known risk of metoclopramide, but the evidence has clear limits—especially regarding early detection and long-term outcomes. This page reviews what current research confirms, where uncertainty remains, and how that shapes monitoring recommendations.
Reglan (metoclopramide) is a prescription medication approved for short-term treatment of symptomatic gastroesophageal reflux in adults and for relief of symptoms in adults with acute and recurrent diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The drug carries a boxed warning stating that metoclopramide, including Reglan, can cause tardive dyskinesia (TD), a potentially irreversible serious movement disorder (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). TD is characterized by involuntary, repetitive movements of the face, tongue, trunk, and extremities, and it may become permanent even after the drug is discontinued. The risk of developing TD increases with the duration of metoclopramide treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with symptomatic gastroesophageal reflux, the maximum approved treatment duration is 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For diabetic gastroparesis, the label advises avoiding total treatment longer than 12 weeks, and if longer use is unavoidable, routine monitoring for TD signs and symptoms is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The label also notes that Reglan may suppress or partially suppress TD signs, potentially delaying diagnosis by masking the underlying disease process (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). From a clinical perspective, TD typically emerges after months or years of exposure, but the timeline between initial Reglan use and documented harm can vary widely. The label emphasizes using Reglan for the shortest duration necessary and periodically reassessing the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). If signs or symptoms of TD develop, Reglan should be discontinued immediately (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, because TD can be irreversible, early detection and cessation are critical. For patients in Florida considering legal action related to Reglan-induced TD, the statute of limitations is a key factor. Florida law generally imposes a two-year statute of limitations for personal injury claims, including those based on prescription drug injuries. The clock typically starts running from the date the injury is discovered, or when it reasonably should have been discovered. Given that TD may develop gradually and its symptoms can be subtle initially, the discovery date may be contested. The label's warning that Reglan can mask TD symptoms further complicates this timeline, as patients and physicians may not recognize the condition until it is advanced.
Settlement-related considerations for affected patients hinge on several factors. First, the adequacy of warnings is central. The Reglan label includes a boxed warning about TD risk, but patients may argue that prescribers did not adequately communicate this risk or that the drug was used beyond the recommended 12-week duration. Evidence shows that the label explicitly states Reglan is not recommended for pediatric use due to TD risk and that longer-term use in adults requires monitoring (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, if a patient was prescribed Reglan for extended periods without proper warnings or monitoring, this could strengthen a claim. Second, the timeline between exposure and documented harm is critical. The label indicates that TD risk increases with cumulative dosage and treatment duration (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Patients who used Reglan for longer than 12 weeks, especially those with diabetic gastroparesis where longer use may be unavoidable, are at higher risk. Medical records documenting the duration of Reglan use, dosage, and onset of TD symptoms are essential for establishing causation. Third, Florida courts may consider whether the manufacturer provided adequate warnings to prescribers and patients. The boxed warning is a strong indicator that the FDA considered the risk significant, but plaintiffs may argue that the warning was insufficiently prominent or that prescribers failed to heed it. The label's contraindication for patients with a history of TD and the recommendation for shortest use suggest that the manufacturer acknowledged the risk, but compliance with these recommendations by prescribers varies. In summary, patients in Florida who developed TD after Reglan use should be aware of the two-year statute of limitations from the date of discovery. The risk is highest with prolonged use beyond 12 weeks, and the label's warnings are explicit. Settlement considerations depend on the duration of use, adequacy of warnings received, and the timeline of harm. Legal counsel should review medical records to establish when TD symptoms first appeared and whether Reglan was used in accordance with labeling. The boxed warning and contraindications provide a basis for claims, but individual circumstances will determine the strength of each case.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Florida law generally imposes a two-year statute of limitations for personal injury claims, including those based on prescription drug injuries. The clock typically starts running from the date the injury is discovered, or when it reasonably should have been discovered. Given that tardive dyskinesia may develop gradually and its symptoms can be subtle initially, the discovery date may be contested. It is important to consult with an attorney promptly to ensure your claim is filed within the applicable timeframe.
Key factors include the duration of Reglan use (especially beyond 12 weeks), the adequacy of warnings provided by the manufacturer and prescriber, the timeline between exposure and documented harm, and whether the drug was used in accordance with labeling. Medical records documenting the duration of use, dosage, and onset of TD symptoms are essential. The boxed warning and contraindications provide a basis for claims, but individual circumstances will determine the strength of each case.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Request archival records or inquire about member-exclusive transition and benefit programs.
Individuals with documented archive exposure and a related diagnosis may request an independent, no-cost eligibility review.